筛选条件 共查询到102条结果
排序方式
LncRNA FGD5-AS1 enhances the proliferation and stemness of hepatocellular carcinoma cells through targeting miR-223 and regulating the expression of ECT2 and FAT1

期刊: HEPATOLOGY RESEARCH, 2022; 52 (7)

Aim Hepatocellular carcinoma (HCC) is common and causes many deaths worldwide. The aim of this study is to explore the mechanism by which long non-cod......

JIF:3.772

Hazard rate for postoperative recurrence in patients with hepatocellular carcinoma at Barcelona Clinic Liver Cancer stage 0 or A1: A multicenter observational study

期刊: HEPATOLOGY RESEARCH, 2022; 52 (11)

Aim Surgical treatment is the first-line treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A1 hepatocellular carcinoma (HCC)......

JIF:3.772

Comparison of anatomical thermal ablation and routine thermal ablation for hepatocellular carcinoma <= 50 mm: A propensity score matching

期刊: HEPATOLOGY RESEARCH, 2022; 52 (7)

Aim The present study was to evaluated the clinical value of anatomical thermal ablation to treat hepatocellular carcinoma compared with routine therm......

JIF:3.772

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study

期刊: HEPATOLOGY RESEARCH, 2022; 52 (9)

Aim Tyrosine kinase inhibitors target transarterial chemoembolization (TACE)-mediated vascular endothelial growth factor to inhibit tumor revasculariz......

JIF:3.772

Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population

期刊: HEPATOLOGY RESEARCH, 2022; 52 (2)

Aim The global burden of chronic liver disease is substantial. Limited studies have reported the prevalence of metabolic dysfunction-associated fatty ......

JIF:3.772

Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma

期刊: HEPATOLOGY RESEARCH, 2022; 52 (8)

Aim Transarterial chemoembolization (TACE) combined with a PD-1 inhibitor and TACE combined with a PD-1 inhibitor and lenvatinib have recently been re......

JIF:3.772

Tumor feeding artery contraction and metastasis inhibition after transarterial chemoembolization combined with apatinib for hepatocellular carcinoma: A propensity score matching study

期刊: HEPATOLOGY RESEARCH, 2022; 52 (6)

Aim To investigate the change of tumor feeding artery diameter and the efficacy of metastasis inhibition after transarterial chemoembolization (TACE) ......

JIF:3.772

Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients

期刊: HEPATOLOGY RESEARCH, 2022; 52 (4)

Aim To summarize HBV-related biomarkers predicting nucleos(t)ide analogs (NAs) discontinuation and hepatitis B virus (HBV) recurrence after drug withd......

JIF:3.772

Circ_0011232 contributes to hepatocellular carcinoma progression through miR-503-5p/AKT3 axis

期刊: HEPATOLOGY RESEARCH, 2022; 52 (6)

Background Hepatocellular carcinoma (HCC) is a type of primary liver cancer with high mortality. Circular RNAs (circRNAs) have been confirmed to be in......

JIF:3.772

ATF2 accelerates the invasion and metastasis of hepatocellular carcinoma through targeting the miR-548p/TUFT1 axis

期刊: HEPATOLOGY RESEARCH, 2022; 52 (3)

Aim Due to high invasion and metastasis, hepatocellular carcinoma (HCC) is known as one of the most fatal carcinomas. We aim to further investigate re......

JIF:3.772

Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred

期刊: HEPATOLOGY RESEARCH, 2021; 51 (6)

Aim To assess the role of consolidation therapy after cessation of nucleoside/nucleotide analogs (NAs) for off-treatment outcome and to explore the op......

Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Outcomes by treatment-emergent ascites

期刊: HEPATOLOGY RESEARCH, 2021; 51 (6)

Aim The REACH and REACH-2 trials investigated ramucirumab versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ascites is common i......

Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease

期刊: HEPATOLOGY RESEARCH, 2021; 51 (6)

Aim This study aimed to analyze the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the indexes of liver fibrosis in patients with typ......

共102条页码: 1/7页15条/页